<<you people are incredibly simple and naive. please grow up. while CELG will be a great company someday its still a little piece of shit. it will give back 2 points on monday. sorry, but thats the way it is.>>
I'm not going to flat out say that it won't, but I will say that the fundamental situation is different now. I've made some pretty good money over the last few years buying in the 7-9 range and selling in the low teens. I think those days are ending though. The company has an FDA approval for one indication, clinical data supporting the use of thalidomide for many other indications are starting to pour in and the first of the second-generation drugs is in the clinic.
Don't forget how excited investors were about the anti-TNF MAb's and Synergen's IL1 receptor antagonist drug back at the beginning of the decade. Those were INJECTABLE drugs that didn't work. Look at the market's more recent reaction to drugs marketed by CNTO and IMNX. Those are injectable too, and expensive. A orally active drug that down-regulates the overproduction of TNF is important, and judging from the clinical evidence that we're seeing thalidomide appears to do the job. The anti-angiogenic properties of the drug are nice too. :-) If this was an entirely new compound that didn't have thalidomide's history CELG would probably be a $20-30 stock right now. Even if it drops back to the 8-10 level tomorrow (and I'm guessing that it won't) the stock's single-digit days are numbered.